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Inhibition of nitric oxide synthase attenuates 
primed microvascular permeability in the in 
vivo microcirculation 
Audra A. Noel, MD, Steve R. FaUek, MD,  Robert  W. Hobson  II ,  MD, and 
Walter N. Durän, PhD, Newark, NJ. 
Purpose: Changes in microvascular permeability play  critical role in the inflammatory 
sequence of tissue injury leading to leakage of proteins and subsequent edema. Primed 
responses induced by topical applications ofplatelet-activating factor (PAF) and histamine 
greatly increase microvascular permeability and mimic inflammation. We assessed the role 
of nitric oxide (NO) by use of l-NG-monomethyl arginine (I-NMMA, a NO synthase 
inhibitor), on the primed microvascular permeability. We also explored the role of mast 
cells and a leukocyte adhesion complex by use of cromolyn sodium and 1B6 (a monoclonal 
antibody), respectively. 
Methods: Forty anesthetized hamsters were separated into five groups: group • (n = 5) 
received no intervention; group 2 (n = 5) received topical 10 -9 mol/L PAF and 10 -6 
mol/L histamine at a 5-minute interval; group 3 (n = 5 at each dose) received 
PAF/histamine and I-NMMA (at 10 -s mol/L or 10 -6 mol/L); group 4 (n = 5 at each dose) 
received cromolyn sodium plus PAF/histamine; group 5 (n = 5) received 1B6 plus 
PAF/histamine. We examined the cheek pouch with intravital videomicroscopy under 
fluorescent epiiUumination. We quantified microvascular permeability to fluorescein 
isothiocyanate-dextran 150 with computer-assisted images analysis on the basis of 
integrated optical intensity (IOI) measurements. 
Results: The mean (+ SEM) IOI of the control group was 8.7 + 5.2, whereas the group 
primed with PAß and histamine was 62.4 + 10.8. The 1-NMMA (10 -~ mol/L and 10 -6 
mol/L) abolished the changes in microvascular permeability (p < 0.05) yielding IOI 
values of 8.0 + 1.6 and 10.9 + 2.8, respectively. Cromolyn sodium and 1B6 did not 
significantly attenuate the primed response to PAF and histamine. 
Conclusion: Inhibition of NO synthase attenuates primed macromolecular extravasation in 
vivo. Out results indicate that NO is involved in the primed reaction of PAF and histamine, 
causing increases in microvascular permeability. Our study suggests a role for NO in the 
microcirculatory changes observed in ischemia-reperfusion njury and shock. (J Vr, sc 
SURG 1995;22:661-70.) 
Microvascular inflammation is a critical compo- 
nent of many clinical disease stares. At the microvas- 
cular level, inflammation causes changes in vessel 
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diameter, adhesion ofleukocytes to the endothelium, 
and increased permeability of postcapillary venules. 
Histamine and platelet-activating factor (PAF) are 
among the chemical substances associated with'these 
microcirculatory reactions in inflammation. The con- 
centrations ofhistamine and ofPAF required to elicit 
inflammation have not been measured accurately in 
vivo. Recently, much attention has been directed at 
priming interactions between agonists.l,2 Priming is 
defined as the amplification of a cell response to a 
given stimulus as a result of  the prior exposure oftläat 
cell to another agonist. Currently, primed responses 
are recognized for their role in the interactions 
between blood cells and the vascular wall and among 
the cellular components of the vascular wall. The 
importance of primed responses is based on the 
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ability of subthreshold concentrations of different 
agonists to produce agreatly amplified response. In 
addition, although the temporal sequence of the 
production and secretion ofinflammatory substances 
in vivo is unknown, it is plausible that their initial 
blood and interstitial concentrations are below 
threshold. 
Histamine and PAF are associated to the inflam- 
matory processes observed clinically in gastrointesti- 
nal ulcers, immune dysfunction, psoriasis, and 
ischemia-reperfusion injury or shock. It is plausible 
that primed responses play a significant role in these 
clinical settings. Our laboratory research objectives 
are to determine and to understand the physiologic 
basis of the complex microvascular changes observed 
in vascular diseases. The achievement of these objec- 
tives will contribute to clinical modalities intended 
for prevention or amelioration of microvascular 
dysfunction and maintenance of cell life. 
Because of the possible role of priming interac- 
tions between histamine and PAF in ischemia- 
reperfusion, we examined further their priming 
interaction leading to a significant increase in mi- 
croväscular permeability when these two mediators 
were given in a time- and dose-controlled manner in 
the in vivo microcirculation. 1 In particular, out study 
was aimed at investigating the role of three possible 
mediators of this permeability change: (1) nitric 
oxide (NO), (2) mast cells, and (3) the leukocyte 
adhesion molectlle CDll/CD18. We hypothesized 
that NO is a possible mediator because it contributes 
to the increase in vascular permeability produced by 
PAF. 3 Mast cells are also candidates because they are 
abundantly and perivascularly present in the hamster 
cheek pouch. 4 Last, on the basis of out demonstra- 
tion that leukopenia nhibited priming interactions, ~ 
we reasoned that blockade of leukocyte adhesion by 
a monoclonal ntibody should decrease the priming 
reaction. To assess the role of NO we used a NO 
synthase inhibitor, whereas we used cromolyn so- 
dium as a mast cell stabilizer and the monoclonal 
antibody 1B6 to inhibit the CDl lb  component of 
the leukocyte adhesion molecule. 
MATERIAL AND METHODS 
Animal preparation. Animal care complied with 
the "Principles of Laboratory Animal Care" (Na- 
tional Society for Medical Research) and the Guidefor 
the Care and Use of Laboratory Animals (NIH 
Publication No. 86-23, revised 1985). Male golden 
Syrian hamsters weighing 90 to 130 gm were 
anesthetized with sodium pentobarbital (65 mg/kg 
intraperitoneally). A tracheostomy robe and two 
right internal jugular vein catheters were placed for 
ventilation and for introduction of anesthetic and 
intravenous medications. Supplemental nesthesia 
was administered intravenously (30 to 50 mg/kg/hr). 
The left hamster cheek pouch was prepared as 
previously described, s,ó Briefly, a two-piece acrylic 
resin chamber with a 1 ml reservoir was secured to 
the single cheek pouch layer. After surgery, the 
hamster was placed on the stage of an intravital 
microscope (Jenalumar, Aus Jena, Germany) 
equipped for fluorescence epiillumination. The ham- 
ster was allowed to stabilize for 1 hour. Bicarbonate 
buffer (pH 7.35; temperature 36 ° C; equilibrated 
with 95% N 2 and 5% CO2) was suffused con- 
tinuously over the cheek pouch throughout he 
experiment. Fluorescein isothiocyanate-dextran 150 
(FITC-dextran 150; Sigma Chemical Co., St. Louis, 
Mo.) was administered after stabilization as a bolus 
(100 mg/kg intravenously) and subsequently as a 
continuous infusion (0.17 mg/min). 
Microvascular permeability determination. 
The cheek pouch was scanned, and three areas of 
postcapillary venules were selected by use of a 10 x 
objective. A television camera (TEC-470, Optronics 
Engineering, Goleta, Calif.) was coupled to a VO- 
5600 videotape recorder (Sony, New York) and used 
to record all experimental data. Computer-assisted 
image analysis with the Image-1 computer system 
(Universal Imaging, West Chester, Pa.) was applied 
to quantify the extravasation f FITC-dextran with 
the integrated optical intensity (IOI) method. 7,8 We 
have demonstrated arlier that measurements of IOI 
in the hamster cheek pouch reflect changes in 
microvascular permeability. This demonstration was 
achieved by development ofa mathematical analytical 
solntion to evaluate the contributions of diffusion 
and convection 9 and calculation from experimental 
data that diffusion constitutes about 90% of the 
driving forces for the transport of FITC-dextran 
150.1° In addition, we have shown that the concen- 
trations of PAF and histamine used in our smdy do 
not have hemodynamic influences.~ For these reasons 
we use the term microvascularpermeability to describe 
the extravasation f macromolecules caused by the 
priming interactions between PAF and histamine. 
Chemical reagents. Platelet activating factor 
(1-O-alkyl-2-O-acetyl-sn-3-phosphocholine; Sigma) 
was initially dissolved in dimethyl sulfoxide (Sigma 
Chemical Co.) to a concentration f 10 -2 mol/L and 
subsequently diluted to 10-9 mol/L with a mixture of 
1.5% bovine serum albumin (Sigma Chemical Co.) 
and bicarbonate buffer. Histamine (diphosphate salt; 
2-[4-imidazolyl] ethylamine; Sigma Chemical Co.) 
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was prepared in normal saline solution to 10-2 mol/L 
and diluted to 10 6 mol/L with bicarbonate buffer. 
Monoclonal antibody 1B6 (MoAb 1B6, a gift 
from Repligen Corporation, Cambridge, Mass.) was 
dissolved in normal saline solution to provide a dose 
of 2 mg/kg. This is a mouse anti-rat monoclonal 
antibody directed against he CDl lb  portion of the 
CDl l /CD18 leukocytic adhesion complex. The 
MoAb 1B6 was tested in vivo for possible cross- 
reactivity with the hamster leukocytes. Cromolyn 
sodium (Sigma Chemical Co.) was prepared in 
normal saline solution and diluted to concentrations 
of 0.5 mg/kg, 2.0 mg/kg, and 10.0 mg/kg for 
intravenous injection. The NO synthase inhibitor, 
l-NG-monomethyl arginine (1-NMMA), was diluted 
in bicarbonate buffer to 10 -s mol/L or 10 -6 mol/L. 
Experimental protocols. Fig. 1 displays the 
time course of the experiments. After surgical prepa- 
ration and stabilization, baseline IO1 measurements 
were made with FITC-dextran 150 used as a macro- 
molecular tracer. In all experiments, except the 
control group, 10 -9 mol/L PAF and 10 6 mol/L 
histamine were applied topically to the che& pouch 
at a 5-minute interval as described previously. 1 The 
1-NMMA, at one concentration per experiment, was 
suffused over the cheek pouch starting 10 minutes 
before the injection of FITC-dextran 150 and extend- 
ing for the remainder of the experiment. Suffusion of 
I-NMMA was chosen as the mode of administration 
to avoid systemic hypertensive effects. MoAb 1B6 
was injected intravenously 10 minutes before the 
application of PAF. Cromolyn sodium was injected 
intravenously either immediately after cannulation of 
the jugular vein (i.e., during surgical preparation) or 
10 minutes before the application of PAF. The 
different times of the intravenous application of 
cromolyn sodium did not affect the results. Three 
doses of cromolyn sodium were tested in different 
experiments. IOI was measured in the selected areas 
at prescribed intervals for the remainder of the 
experimental observation period. 
Experimental groups. Forty hamsters were 
separated into five groups. Group 1 (n = 5) had no 
intervention and served as the baseline control. 
Group 2 (n = 5) received topical 10 -9 mol/L PAF 
and 10 -6 mol/L histamine at a 5-minute interval and 
exemplified the priming reaction. Group 3 (n = 5 at 
each dose) received PAF/histamine and 1-NMMA at 
10 5 mol/L or 10 -6 mol/L. Group 4 (n = 5 at each 
dose) was treated with PAF/histamine plus cromolyn 
sodium at 0.5 mg/kg, 2.0 mg/kg, or 10.0 mg/kg. 
Group 5 (n = 5) received monoclonal antibody 1B6 
at 2 mg/kg in addition to PAF/histamine. 
Statistics. For analytical purposes, the maximal 
IOI valucs were used and expresscd as mean _+ 
standard error of the mean (SEM). Data were 
evaluated for statistieal significance with the analysis 
ofvariance and the Student-Newman-Keuls multiple 
comparisons test, with appropriate corrections. Dif- 
ferences were considered significant atp < 0.05. 
RESULTS 
Time course of extravasation. Control animals 
showed minimal leakage throughout he experi- 
ment, whereas the animals treated with the priming 
sequence of 10 -9 mol/L PAF and 10 -6 mol/L 
histamine topically at a 5-minute interval had a peak 
IOI value at 40 minutes after the application of 
histamine (Fig. 2). The addition of 1-NMMA (10-5 
mol/L and 10 -6 mol/L) greatly attenuated this 
change in permeability (Fig. 2). The addition of 
cromolyn sodium did not affect the maximal IOI 
value, but the peak permeability occurred earlier (20 
to 30 minutes after priming). The group treated 
with MoAb 1B6 had increasing macromolecular 
permeability hroughout the experiment. Regardless 
of the time course, the maximal IOI values achieved 
with cromolyn sodium and with MoAb 1B6 were 
similar to those in the priming group that received 
only PAF and histamine. 
Role of NO. The control group showed a 
maximal FITC-dextran extravasation of 8 .7 -  
5.2 units, whereas the group treated with PAF 
and histamine priming had an IO1 value of 
62.4 _+ 10.8 tmits (Fig. 3). Those animals treated 
topically with 1-NMMA at 10 -s mol/L had com- 
plete attenuation of the increase in macromolecular 
permeability with peak IOI values of 8.0 +_ 1.6. 
Similarly, animals given 10 -6 mol/L 1-NMMA had 
an IO1 of 10.9 _+ 2.8 units (Fig. 3). This attenu- 
ation represented a significant difference for both 
doses of 1-NMMA as compared with the priming 
group. 
Role of mast cells. Animals given cromolyn 
sodium 0.5 mg/kg, 2.0 mg/kg, and 10.0 mg/kg 
intravenously had peak macromolecular I01values of 
66.9 + 11.2, 50.6 _+ 16.7, and 77.0 +_ 20.9, re- 
spectively (Fig. 4). These values are statistically 
similar to the priming group. 
The FITC-dextran extravasation in the cromolyn 
sodium-treated animals appeared in a linear streaking 
pattern. This observation is in contrast to the vascular 
permeability seen in the circulation challenged with 
agonists such as bradykinin, adenosine, PAF, and 
histamine. 5,n The more commonly observed leakage 
patterns are circular "hot spots" visible adjacent to 
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Fig. 1. Time sequence for experimental protocols. Data were videorecorded during baseline 
period (at 10, 20, and 30 minutes) and during the experiment (at 5, 10, 15, 20, 30, 40, 50, and 
60 minutes after priming). Data were analyzed with integrated optical intensity at conclusion 
of experiment. PAl: (10 -9 mol/L) and histamine (10 -6 mol/L) were given at same 
concentrations at 5-minute interval in every group except control group. Each other 
pharmacologic agent wastested in separate experiments. 
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Fig. 2. Time course of changes in microvascular permeability in animals treated with I-NMMA 
plus PAF/histamine priming, Mean IOI value at each time point after priming is shown. Peak 
permeability occurs at 40 minutes after priming in PAF/histamine treated group. This increase 
is abolished in groups treated with I-NMMA. 
microvessels. The significance of this anatomic dif- 
ference is unclear. 
Role of the leukocyte adhesion complex. The 
statistical analysis of  the maximal IOI in the hamsters 
treated with MoAb 1B6 is shown in Fig. 5. This 
group had a peak IOI of 42.8 _+ 9.3. Although there 
was an apparent trend for a decrease relative to the 
PAF/histamine priming IOI value, the difference was 
not significant. 
D ISCUSSION 
Microvascular permeability alterations are a criti- 
cal component of inflammation. Together with 
vasomotor changes and leukocyte adhesion, extrava- 
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Fig. 3. Statistical nalysis of microvascular permeability. Five animals were examined in each 
group. Data are presented as mean maximal IOI value _+ SEM. Group treated with PAF and 
histamine priming alone shows ixfold increase in permeability. This permeability is completely 
attenuated in groups treated with 1-NMMA at both 10 s mol/L and 10 -6 mol/L. (~ represents 
p < 0.01 compared with control; # represents p < 0.01 compared with I-NMMA) 
sation of plasma proteins causes ubsequent edema. 
Microvascular inflammation is one of the compo- 
nents of the clinical sequelae of shock, asthma, 
gastrointestinal ulceration, immune disorders, and 
ischemia-reperfusion injury. Because the precise time 
course of secretion and required concentrations of
proinflammatory substances in clinicaily relevant 
vascular diseases are unknown, and because priming 
interactions are recognized as potentially important 
for the onset of inflammatory eactions, we investi- 
gated possible mechanisms involved in the primed 
increase in microvascular permeability cansed by PAF 
and histamine. Both agonists at high concentrations 
are involved in eliciting microvascular inflammation 
and have been reported as possible factors in inflam- 
matory vascular diseases. 
PAF causes three major effects on the micro- 
circulation: vasoconstriction, leukocyte adhesion, 
and increase in microvascular permeability o macro- 
molecules, ha3 These PAF effects are receptor medi- 
ated and can be inhibited by synthetic and namral 
antagonists. 14,15 Another agent, histamine, has also 
been implicated in postcapillary venular permeability, 
vasodilation, and leukocyte rolling via P-selectin. 16 
The priming interaction of PAF with histamine has 
been weil defined. 1 If given alone, 10 -9 mol/L PAF 
has no effect on microvascular permeability but 
causes increased leukocyte adhesion.12 If  given alone, 
10-6 mol/L histamine has no effect on microvascular 
permeability. However, when 10 -9 mol/L PAF is 
given before 10 -6 mol/L histamine, it causes a dra- 
matic increase in macromolecular extravasation. This 
may represent inflammation atits earliest stage when 
the concentrations of PAF and histamine are very 
low. The priming between these two inflammatory 
mediators is time dependent, leukocyte dependent, 
and receptor mediated. The maximal increase in mi- 
crovascular permeability occurs when the mediators 
are given at a 5-minute interval. PAF primes the 
microcirculation when given before histamine. In ad- 
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Fig. 4. Statistical nalysis of role of mast cells in PAF/histamine priming. Mast cell stabilizer 
cromolyn sodium (CRNA) was given at three doses. Five animals were treated at each dose. Data 
represent mean maximal IOI value _+ SEM. No significant change in permeability was observed 
in CRNA-treated animals as compared with PAF/histamine priming group. (2 represents 
p < 0.05 compared with control). 
dition, this increase in microvascular permeability is 
observed when 10 6 mol/L histamine isgiven before 
10 -9 mol/L PAF. 
In this report, to understand further the regula- 
tion of priming interactions, we examined three 
factors for their possible role in the control of the 
primed change in microvascular permeability to 
macromolecules. 
Role of NO. NO is an inorganic free radical gas 
synthesized from 1-arginine by vascular endothelial 
cells. 17 Its role in microvascular inflammation is still 
controversial. One laboratory has shown that inhibi- 
tion of NO synthase caused increased postcapillary 
venular permeability and leukocyte adherence in the 
rat mesentery. 18'~9 However, other laboratories 2°,21 
have shown decreased changes in vascular permeabil- 
ity after NO synthase inhibition in pig coronary 
venules and in the hamster cheek pouch. 
Our data demonstrate that NO serves as a 
mediator in the PAF/histamine-primed increases in 
microvascular permeability o macromolecules. This 
conclusion is supported by the complete attenuation 
of the primed response by the 1-arginine analog, 
1-NMMA. In a separate smdy, we have shown that 
I-NMMA blocks the acetylcholine-vasodilation in the 
hamster cheek pouch as an indirect pharmacologic 
evidence of the efficacy of 1-NMMA to block the 
activity of NO synthase. 3 
The discrepancy between our findings and those 
reported in the mesenteric vasculature may be due to 
differences in model types, that is, the use of 
mesenter ic  tissue 17 versus the hamster cheek pouch. 
These divergent observations suggest hat the rat 
mesentery responds differently to NO or reactive 
oxygen metabolites than other animal tissues, thus 
complicating the understanding ofthe role of NO in 
the clinical scenario. 
Thus it is uncertain whether increased NO 
production is beneficial or injurious. This variance 
has been reported in models of shock and of 
reperfusion i jury. For example, in endotoxic shock, 
NO synthase inhibitors restore blood pressure and 
improve myocardial, pulmonary, and renal func- 
tion. 22 Also patients with sepUc shock have elevated 
NO production. 23 Similarly, in a rat model of 
hemorrhagic shock, the use of another NO synthase 
inhibitor (NG-nitro-l-arginine methyl ester) attenu- 
ates vascular decompensation. 24 Conversely, in a 
cardiac model of ischemia-reperfusion injury, NO is 
beneficial.25 Ischemic myocardium has decreased NO 
production after reperfusion, leading to accumula- 
tion of neutrophils and subsequent myocardial cell 
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PAF/histamine priming. Monoclonal antibody (MoAblB6) was given to five hamsters. Data are 
presented as mean maximal IOI value _+ SEM. Compared with PAF/histamine priming group, 
animals treated with MoAblB6 had slightly decreased IOI, but difference was not significant. 
(* represents p < 0.05 compared with control). 
injury. 2s Myocardial infarct size can be reduced by 
treatment with 1-arginine, which is the substrate for 
NO synthase. 26
These clinically relevant examples may represent 
different signaling pathways timulated by NO. The 
interactions of NO with complex signaling molecules 
(including calmodulin, calcium, protein kinase C, 
tyrosine kinase, phospholipase A2, cyclic guanosine 
monophosphate, and cyclic adenosine monophos- 
phate) may vary depending on their relative concen- 
trations and the overall physiologic status of the cell. 
Further research accounting for these variables is 
necessary to establish the role of NO in vascular 
syndromes. 
Role of mast cells. Cromolyn sodium has been 
used for more than 10 years as a clinical mast cell 
stabilizer in human beings for prophylactic treatment 
of asthma and allergic rhinitis. It is reported to 
prevent mast cell degranulation and thus prevent the 
release of inflammatory mediators. The exact actions 
of cromolyn sodium have not been fully elucidated, 
but its mechanisms include reduction of calcium 
transport across mast cell membranes, inhibition of 
the calcium-dependent degranulation process and 
accumulation of cyclic adenosine monophosphate. 27 
The three doses of cromolyn sodium used in our 
experiments reflect he dosage given to human beings 
(approximately 0.75 to 1.5 mg/kg) and are effica- 
cious as a prophylactic treatment. In this study the 
compound id not attenuate he change in microvas- 
cular permeability at any dose as compared with the 
priming group. This lack of inhibition was indepen- 
dent of the time of intravenous administration of 
cromolyn sodium. The two modalities, approxi- 
mately 1.5 hours before the priming sequence (after 
the cannulation of the jugular vein) and 5 minutes 
before the priming sequence, were applied to mimic 
prophylactic and acute administration. Although the 
data indicate an apparent lack ofparticipation ofmast 
cells in priming, caution should be exercised because 
mast cells may degranulate and stimulate inflamma- 
tion immediately with the onset of the surgical 
preparation (Fig. 1). 
Role of the leukocyte adhesion complex. The 
monoclonal antibody 1Bö is a mouse anti-rat anti- 
body selective for the CDI Ib  portion of the leuko- 
cyte adhesion complex (CDll/CD18). The purpose 
of investigating this adhesion complex is due to the 
importance of leukocyte-endothelial interaction in 
inflammation. This interaction likely begins with 
leukocyte rolling, proceeds to leukocyte-endothelial 
adherence, then progresses to leukocyte migration 
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into the interstit ium accompanied by protein leakage. 
Adhesion glycoproteins mediate this process. It  is 
believed that the progression o f  leukocyte adherence 
to emigrat ion is inevitable once the inf lammatory 
process has begun. However ,  in in vivo microcircu- 
latory models, PAF  given topically at 10 -9 mol /L  
increases leukocyte adherence without any increase in 
microvascular permeabi l i ty to macromolecules, n 
The role o f  leukocyte adhesion complexes is 
usually examined with the aid o f  monoclonal  anti- 
bodies. 28,29 Currently there are no specific anti- 
hamster CD 11/CD18 antibodies to complement  our 
microcirculatory model.  However ,  some antibodies 
elicit cross-reactivity to other species. Thus the MoAb 
1B6 was used in an effort to determine the role o f  the 
leukocyte-endothel ial  adhesion complex in the prim- 
ing reaction. A l though the animals treated with 
MoAb 1B6 had decreased mean IO I  values, the 
difference was not  significant. This likely represents 
the lack o f  conservation o f  epimpes between these 
two animals. 
In summary,  we have shown that NO plays a role 
in the regulat ion o f  PAF/h is tamine-pr imed microvas- 
cular permeabi l i ty responses in the in vivo microcir- 
culation. Knowledge o f  the precise interactions 
involved in pr imed reactions will increase our under- 
standing o f  microvascnlar inf lammation and may 
provide a basis for therapeutic interventions in the 
management  o f  ischemia-reperfusion injury, as weil 
as possibly other important  clinical vascular syn- 
dromes. 
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DISCUSSION 
Dr. Gary A. Fantini (New York, N.Y.). Increased 
microvascular permeability is a well-established phenom- 
enon accompanying reoxygenation i jury of various post- 
ischemic tissues, including skeletal muscle. As vascular 
surgeons we recognize this clinically as compartment 
syndrome. These well-conceived and well-presented xperi- 
ments alm to elucidate mechanisms of microcirculatory 
leak with specific attention to the role of NO, as weil as to 
the potential roles of mast cell degranulation and neutro- 
phil adhesion. The authors have previously shown that 
topically applied PAF causes macromolecular leakage into 
the interstitial compartment of the hamster cheek pouch 
model in a dose-response fashion. These resuks demon- 
strate that NO synthase inhibition abrogated this increase. 
In contrast, no significant effects were observed with 
cromolyn sodium, which is a mast cell stabilizing agent, or 
anti-CDllb antibody, which is an anti-neutrophil adhe- 
sion antibody. 
These results may be explained by the following 
mechanisrn: because the H-1 receptor-mediated effect of 
histamine is an indirect one occurring via stimulation of 
calcium-dependent dothelial NO synthase, pretreatment 
with N6-monomethyl arginine blocks NO synthesis and 
thus attenuates the increase in microvascular permeability 
associated with the PAF/histamine priming reaction. Do 
you agree with this postulated mechanism of action or do 
you believe that other pathways are involved? 
The putative role of NO in this setting would be further 
strengthened bydata demonstrating increased microvascu- 
lar permeability with suffusion of authentic NO, or by 
measuring a marker of NO generation such as cyclic 
guanosine monophosphate. Have these experiments been 
done? 
With regard to the mechanism of the PAF/histamine 
priming reaction, are you postulating that this occurs via 
up-regulation of NO release or via alteration in tissue 
susceptibility to the effects of NO, or via alternate 
mechanisms? Have you tested the effect of H-1 receptor 
antagonists and, if so, was the effect comparable to that 
achieved with inhibition of NO synthesis? 
Dimethyl sulfoxide (DMSO), a hydroxyl radical scav- 
enger, was chosen as a vehicle for PAF. Because PAF may 
prime certain neutrophil responses including oxidant 
generation, is it possible that this vehicle may act to 
ameliorate this particular PAF-induced response? 
And finally, neutrophil adherence to the Mac-1 adhe- 
sion complex has been shown to play an important, if not 
critical, role in mediating the increase in microvascular 
permeability accompanying reperfusion of postischemic 
skeletal muscle. Would you speculate about why pretreat- 
ment with the anti-CDllb antibody failed to prevent 
increased microvascular permeability in this model? 
Dr. Audra A. Noel. Our laboratory has reported that 
pyrilamine, a histamine-1 antagonist, does inhibit the 
priming effect between PAF and histamine. We then tested 
the hypothesis that histamine or PAF may activate a 
calcium-dependent mechanism of NO synthase. Our re- 
sults support his hypothesis because, by inhibiting NO 
synthesis with 1-NMMA, we are able to block the 
PAF/histamine priming effect. Other experiments in our 
laboratory demonstrate hat calcium-dependent pathways 
partially regulate microvascular inflammation. 
DMSO was used only for the initial solution of PAF. 
Only 10 }~1 DMSO was diluted in bicarbonate buffer and 
albumin and then further diluted to achieve the appropriate 
concentration of PAF (10 _9 mol/L). This low concentra- 
tion of DMSO does not affect he PAF-induced response. 
Concerning the CDl l -CD18 antibody, we used a 
monoclonal antibody, 1B6, to attempt to inhibit the 
CDl lb  portion of the adhesion molecule, but no signifi- 
cant reduction of the primed permeability change was 
observed. This antibody is actually a mouse anti-rat 
antibody. These results uggest a lack ofconservation f the 
appropriate pitopes in this situation. We were unable to 
obtain a monoclonal ntibody directed against the hamster 
CD11/CD18 complex. 
Dr. Thomas F. Panetta (Brooklyn, N.Y.). You've 
showed that calcium channel antagonists partially inhibit 
the macromolecular eak, whereas the NO synthase inhibi- 
tors completely abolish this. What's the relationship 
between the calcium channel antagonists and the NO 
synthase inhibitors with regard to the mechanism? 
Did you see any vasoreactivity changes in this model? 
I know you used a smaller dose, 10 -9 PAF; did that cause 
any vasoreactive changes? The calcium channel antagonists, 
because they don't inhibit the vasoreactivity then is that an 
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NO-mediated response, and are you considering looking at 
that with regard to the ability of the NO synthase inhibitors 
in preventing the vasoreactivity induced by PAF? 
Dr. Noel. Several experiments have been done in out 
laboratory to elucidate the role of calcium channel blockers 
in microvascular inflammation. We believe that the 
calcium-dependent mechanisms may occur earlier in the 
cascade of events leading to changes in microvascular 
permeability, whereas activation of NO synthase may occur 
later. Also, multiple signaling pathways may activate NO 
synthase. Therefore by inhibiting NO synthase rather than 
an earlier step in the signaling cascade, we are able to 
completely attenuate pcrmcability changcs. 
We did not examine vasoreactivity specifically in this set 
of experiments. However, we have shown in the past that 
the concentrations of PAF and histaminc involved in the 
priming reaction do not cause vasoconstriction r dilation 
of the microvessels. The application of a NO synthase 
inhibitor did not affect vasoreactivity significantly. We 
hypothcsize that NO-cyclic guanosine monophos- 
phate-dependent vasodilation plays an important role in 
the normal control of blood flow. 
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